{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:47:34Z","timestamp":1792205254773,"version":"4.4.0"},"reference-count":129,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TA.2011.40200.044"],"award-info":[{"award-number":["TA.2011.40200.044"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["90729"],"award-info":[{"award-number":["90729"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Moxifloxacin, an 8\u2010methoxy quinolone, is an important drug in the treatment of multidrug\u2010resistant tuberculosis and is being investigated in novel drug regimens with pretomanid, bedaquiline, and pyrazinamide, or rifapentine, for the treatment of drug\u2010susceptible tuberculosis. Early results of these studies are promising. Although current evidence does not support the use of moxifloxacin in treatment\u2010shortening regimens for drug\u2010susceptible tuberculosis, it may be recommended in patients unable to tolerate standard first\u2010line drug regimens or for isoniazid monoresistance. Evidence suggests that the standard 400\u2010mg dose of moxifloxacin used in the treatment of tuberculosis may be suboptimal in some patients, leading to worse tuberculosis treatment outcomes and emergence of drug resistance. Furthermore, a drug interaction with the rifamycins results in up to 31% reduced plasma concentrations of moxifloxacin when these are combined for treatment of drug\u2010susceptible tuberculosis, although the clinical relevance of this interaction is unclear. Moxifloxacin exhibits extensive interindividual pharmacokinetic variability. Higher doses of moxifloxacin may be needed to achieve drug exposures required for improved clinical outcomes. Further study is, however, needed to determine the safety of proposed higher doses and clinically validated targets for drug exposure to moxifloxacin associated with improved tuberculosis treatment outcomes. We discuss in this review the evidence for the use of moxifloxacin in drug\u2010susceptible tuberculosis and explore the role of moxifloxacin pharmacokinetics, pharmacodynamics, and drug interactions with rifamycins, on tuberculosis treatment outcomes when used in first\u2010line tuberculosis drug regimens.<\/jats:p>","DOI":"10.1002\/jcph.968","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T01:02:33Z","timestamp":1500944553000},"page":"1369-1386","source":"Crossref","is-referenced-by-count":64,"title":["A Review of Moxifloxacin for the Treatment of Drug\u2010Susceptible Tuberculosis"],"prefix":"10.1002","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9550-9501","authenticated-orcid":false,"given":"Anushka","family":"Naidoo","sequence":"first","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA) University of KwaZulu\u2010Natal Durban South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA) University of KwaZulu\u2010Natal Durban South Africa"},{"name":"MRC\u2010CAPRISA HIV\u2010TB Pathogenesis and Treatment Research Unit Doris Duke Medical Research Institute University of KwaZulu\u2010Natal Durban South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology Department of Medicine University of Cape Town Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Essack","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Unit School of Health Sciences University of KwaZulu\u2010Natal Durban South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesri","family":"Padayatchi","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa (CAPRISA) University of KwaZulu\u2010Natal Durban South Africa"},{"name":"MRC\u2010CAPRISA HIV\u2010TB Pathogenesis and Treatment Research Unit Doris Duke Medical Research Institute University of KwaZulu\u2010Natal Durban South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Global Tuberculosis Report 2016","author":"WHO","year":"2016"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60916-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0627"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/651493"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00063-6"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.3.393"},{"key":"e_1_2_9_8_1","volume-title":"South African National Tuberculosis Management Guidelines","author":"South African Department of Health","year":"2014"},{"key":"e_1_2_9_9_1","volume-title":"Global Tuberculosis Report 2015","author":"WHO","year":"2015"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01377-15"},{"key":"e_1_2_9_11_1","first-page":"1","article-title":"Moxifloxacin: an alternative to ethambutol for the treatment of presumed ocular tuberculosis","author":"Potter J","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62002-X"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407426"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314210"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0080-2015"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200310-1380OC"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-885OC"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-360OC"},{"issue":"2","key":"e_1_2_9_19_1","first-page":"128","article-title":"A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee R","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60333-0"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067030"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu550"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1413919"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70885-0"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"issue":"6","key":"e_1_2_9_26_1","first-page":"577","article-title":"Shorter moxifloxacin\u2010based regimens for drug\u2010sensitive tuberculosis","volume":"372","author":"Sellier PO","year":"2015","journal-title":"N Engl J Med"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0085-2015"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1414718"},{"issue":"6","key":"e_1_2_9_29_1","first-page":"577","article-title":"Shorter moxifloxacin\u2010based regimens for drug\u2010sensitive tuberculosis","volume":"372","author":"Gillespie SH","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/cid\/civ911","article-title":"Shortening tuberculosis treatment with fluoroquinolones: lost in translation?","volume":"62","author":"Lanoix JP","year":"2016","journal-title":"Clin Infect Dis"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1410977"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/599040"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1086\/424849"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.895813"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211797470192"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01478-13"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0935"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1086\/521894"},{"issue":"6","key":"e_1_2_9_40_1","first-page":"979","article-title":"Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin","volume":"136","author":"Ramachandran G","year":"2012","journal-title":"Indian J Med Res"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01621-06"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00404-12"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3200"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00176610"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1086\/605576"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70264-5"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00337-X"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.1.101"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00671-6"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-06"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802609789630947"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1517-838246320140507"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88306-X"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2345"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.6.835"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2000.36.4.570201"},{"issue":"2","key":"e_1_2_9_57_1","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0022-3565(24)36897-1","article-title":"Transport of quinolone antibacterial drugs by human P\u2010glycoprotein expressed in a kidney epithelial cell line, LLC\u2010PK1","volume":"282","author":"Ito T","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00064-9"},{"key":"e_1_2_9_59_1","volume-title":"Moxifloxacin Invetigator Brochure Version 14.0","author":"Bayer HealthCare AG.","year":"2011"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_2.83"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140001-00003"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140001-00006"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140001-00008"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528090-00004"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx004"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.9.4001"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140050-00002"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00554-08"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202411"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.8.2060"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.8.2.181"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.11.2793"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01036-07"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.04.019"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2015.56.4.961"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.12.027"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154778"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu868"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/1545109712454454"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/108291"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01833-10"},{"issue":"8","key":"e_1_2_9_82_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3855\/jidc.4696","article-title":"Low rifampicin concentrations in tuberculosis patients with HIV infection","volume":"8","author":"Gengiah TN","year":"2014","journal-title":"J Infect Dev Countries"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1086\/598192"},{"key":"e_1_2_9_84_1","first-page":"89","article-title":"Role of pharmacogenomics in the treatment of tuberculosis: a review","volume":"5","author":"Ramachandran G","year":"2012","journal-title":"Pharmgenomics Pers Med"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000024"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12884"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283385a1c"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201407-1264OC"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.15.0577"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-06"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1086\/314059"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks033"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv360"},{"key":"e_1_2_9_95_1","article-title":"Population\u2010based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","author":"Zignol M","journal-title":"Lancet Infect Dis"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2006.12.7"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00287-09"},{"key":"e_1_2_9_98_1","first-page":"223","article-title":"Moxifloxacin resistance in the F15\/LAM4\/KZN extensively drug\u2010resistant strain of Mycobacterium tuberculosis","volume":"7","author":"Dookie N","year":"2014","journal-title":"Infect Drug Resist"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00539-16"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.21"},{"issue":"1","key":"e_1_2_9_101_1","first-page":"21","article-title":"Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes","volume":"41","author":"Canetti G","year":"1969","journal-title":"Bull World Health Organ"},{"key":"e_1_2_9_102_1","volume-title":"Guidelines for the programmatic management of drug\u2010resistant tuberculosis","author":"WHO","year":"2008"},{"key":"e_1_2_9_103_1","volume-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug\u2010Resistant Tuberculosis","author":"WHO","year":"2014"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh119"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.9.3977-3979.2005"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1086\/340618"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90170-1"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00064-11"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488612802715735"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.2165\/11634300-000000000-00000"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0078OC"},{"issue":"8","key":"e_1_2_9_112_1","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/AAC.42.8.2066","article-title":"In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis","volume":"42","author":"Ji B","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3482-3486.2001"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.653-657.2003"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.340-343.2004"},{"issue":"6","key":"e_1_2_9_116_1","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson JL","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00139-10"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06383-11"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201212-2328OC"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00074-08"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200305-682OC"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.780-782.2004"},{"key":"e_1_2_9_123_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki376"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"issue":"1","key":"e_1_2_9_125_1","first-page":"65","article-title":"Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis","volume":"14","author":"Wang JY","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_9_126_1","first-page":"Cd004795","article-title":"Fluoroquinolones for treating tuberculosis (presumed drug\u2010sensitive)","volume":"6","author":"Ziganshina LE","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_127_1","doi-asserted-by":"publisher","DOI":"10.1086\/508278"},{"key":"e_1_2_9_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11467-8"},{"key":"e_1_2_9_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.03.017"},{"key":"e_1_2_9_130_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02048-12"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:41:36Z","timestamp":1750786896000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":129,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/jcph.968"],"URL":"https:\/\/doi.org\/10.1002\/jcph.968","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]}}}